Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | AXL | P30530 | 1/20 | 0.41 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 4/20 | 0.38 |
| ▸ | GSK3B | P49841 | 5/20 | 0.37 |
| ▸ | CDK5 | Q00535 | 5/20 | 0.37 |
| ▸ | CCNB2 | O95067 | 4/20 | 0.37 |
| ▸ | CDK1 | P06493 | 4/20 | 0.37 |
| ▸ | CCNB1 | P14635 | 4/20 | 0.37 |
| ▸ | CCNB3 | Q8WWL7 | 4/20 | 0.37 |
| ▸ | CDK5R1 | Q15078 | 4/20 | 0.37 |
| ▸ | DAO | P14920 | 1/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29573599 | 1.00 | ALDH1A1 (0.41) | ALDH1A1AXLNUDT1NR4A2RIPK1 | |
| SCHEMBL15633796 | 0.78 | NPC1 (0.46) | ALDH1A1AXLNUDT1GSK3BCDK5 | |
| SCHEMBL279584 | 0.75 | PARP1 (0.44) | ALDH1A1AXLNUDT1GSK3BCDK5 | |
| SCHEMBL4353284 | 0.75 | DAO (0.44) | ALDH1A1AXLNUDT1RIPK1GSK3B | |
| SCHEMBL4361479 | 0.75 | ALDH1A1 (0.41) | ALDH1A1AXLNUDT1RIPK1GSK3B | |
| SCHEMBL13569110 | 0.75 | ALDH1A1 (0.41) | ALDH1A1AXLNUDT1RIPK1GSK3B | |
| SCHEMBL3543546 | 0.75 | ALDH1A1 (0.41) | ALDH1A1AXLNUDT1RIPK1GSK3B | |
| SCHEMBL31325494 | 0.75 | ALDH1A1 (0.41) | ALDH1A1AXLNUDT1RIPK1GSK3B | |
| SCHEMBL31197525 | 0.75 | DAO (0.44) | ALDH1A1AXLNUDT1RIPK1GSK3B | |
| SCHEMBL29726335 | 0.75 | NUDT1 (0.50) | ALDH1A1AXLNUDT1RIPK1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4634170-A1 | IMIDAZO[4,5-B]PYRIDINE DERIVATIVES AS PCSK9 INHIBITORS AND METHODS OF USE THEREOF | AstraZeneca AB (SE) | 2025-10-22 | — | — | EP | disclosed |
| US-20240239767-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-07-18 | — | — | US | disclosed |
| WO-2024126773-A1 | IMIDAZO[4,5-B]PYRIDINE DERIVATIVES AS PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-06-20 | — | — | WO | disclosed |
| US-20230242512-A1 | ISOINDOLINES AS HDAC INHIBITORS | VALO HEALTH, INC. | 2023-08-03 | — | — | US | disclosed |
| US-20230242512-A1 | ISOINDOLINES AS HDAC INHIBITORS | VALO HEALTH, INC. | 2023-08-03 | — | — | US | disclosed |
| US-20230242512-A1 | ISOINDOLINES AS HDAC INHIBITORS | VALO HEALTH, INC. | 2023-08-03 | — | — | US | disclosed |
| US-11535607-B2 | Isoindolines as HDAC inhibitors | VALO HEALTH, INC. (US) | 2022-12-27 | — | — | US | disclosed |
| US-20210253555-A1 | ISOINDOLINES AS HDAC INHIBITORS | VALO EARLY DISCOVERY, INC. (US) | 2021-08-19 | — | — | US | disclosed |
| EP-3784654-A1 | ISOINDOLINES AS HDAC INHIBITORS | Valo Early Discovery, Inc. (US) | 2021-03-03 | — | — | EP | disclosed |
| CN-112292370-A | Isoindolines as HDAC inhibitors | 瓦洛早期发现股份有限公司 | 2021-01-29 | — | — | CN | disclosed |
| US-8563575-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-10-22 | — | — | US | disclosed |
| US-8563575-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-10-22 | — | — | US | disclosed |
| US-20130172328-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASES (PDES) INHIBITORS | CROSSWING INC. (CA) | 2013-07-04 | — | — | US | disclosed |
| US-20130172328-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASES (PDES) INHIBITORS | CROSSWING INC. (CA) | 2013-07-04 | — | — | US | disclosed |
| US-20130172328-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASES (PDES) INHIBITORS | CROSSWING INC. (CA) | 2013-07-04 | — | — | US | disclosed |
| WO-2011163355-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASES (PDES) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-12-29 | — | — | WO | disclosed |
| WO-2011163355-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASES (PDES) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-12-29 | — | — | WO | disclosed |
| US-20110319394-A1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-12-29 | — | — | US | disclosed |
| US-20110319394-A1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-12-29 | — | — | US | disclosed |
| US-20110319394-A1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11535607-B2 | Isoindolines as HDAC inhibitors | HDAC1, HDAC2, HDAC3 | ALDH1A1 1182/4885AXL 4386/4885NUDT1 4564/4885 |
| US-20230242512-A1 | ISOINDOLINES AS HDAC INHIBITORS | HDAC1, HDAC2, HDAC3 | ALDH1A1 1133/4885AXL 4407/4885NUDT1 4570/4885 |
| US-20130172328-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASES (PDES) INHIBITORS | PDE3A, PDE5A, PDE2A | ALDH1A1 166/4885AXL 4763/4885NUDT1 561/4885 |
| US-20240239767-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | PCSK9, PCSK7, PCSK6 | ALDH1A1 4278/4885AXL 1934/4885NUDT1 2287/4885 |
| US-20110319394-A1 | FUSED HETEROCYCLIC COMPOUNDS | PDE5A, PDE2A, PDE3A | ALDH1A1 135/4885AXL 4384/4885NUDT1 517/4885 |
| US-20210253555-A1 | ISOINDOLINES AS HDAC INHIBITORS | HDAC1, HDAC2, HDAC3 | ALDH1A1 1182/4885AXL 4386/4885NUDT1 4564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.